Who owns KPTI?
Institutional ownership of Karyopharm Therapeutics Inc. from Form 13F, Q2 2026
96 institutional managers reported holding Karyopharm Therapeutics Inc. (KPTI) in Form 13F filings for Q2 2026, with 21,800,042 shares worth $213M. The largest reported holder was Ra Capital Management, L.p. Managers that filed both quarters added a net 3,754,760 shares (+20.8%). 34 opened new positions and 14 sold out.
- Funds holding
- 96
- Value held
- $213M
- New / sold out
- 34 / 14
- Net shares, same filers
- +20.8%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of KPTI
Share of 13F holdings is each fund's shares as a share of the 21,800,042 KPTI shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Kalehua Capital Management LLC New+$13.4M
- Acorn Capital Advisors, LLC Added+$12.0M
- BlackRock, Inc. Added+$11.5M
- NEA Management Company, LLC New+$5.6M
- Two Sigma Investments, LP Added+$5.3M
- Ghisallo Capital Management LLC New+$4.9M
- Goldman Sachs Group Inc Added+$4.7M
- Geode Capital Management, LLC Added+$3.2M
- Silverarc Capital Management, LLC New+$2.9M
- State Street Corp Added+$2.4M
Biggest sellers in Q2 2026
- Commodore Capital LP Sold out-$10.9M
- T. Rowe Price Investment Management, Inc. Trimmed-$7.4M
- Ikarian Capital, LLC Sold out-$4.1M
- Adage Capital Partners GP, L.l.c. Trimmed-$2.8M
- Affinity Asset Advisors, LLC Trimmed-$1.8M
- Jump Financial, LLC Trimmed-$1.6M
- Boothbay Fund Management, LLC Sold out-$1.2M
- Millennium Management LLC Trimmed-$1.1M
- XTX Topco Ltd Trimmed-$1.1M
- Group One Trading LLC Sold out-$1.1M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $89.5M and sold $38.0M; 29 added and 14 trimmed.
Schedule 13D and 13G filings on KPTI
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-09-04INTEGRATED CORE STRATEGIES (US) LLC SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2026-07-28BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-05-12GOLDMAN SACHS GROUP INC SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2026-04-02RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2026-04-02Commodore Capital LP SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2026-02-10INTEGRATED CORE STRATEGIES (US) LLC SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2025-07-16JPMORGAN CHASE & CO SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
Questions about KPTI ownership
- Who owns KPTI stock?
- 96 institutional investment managers reported KPTI positions in their Form 13F filings for Q2 2026, holding 21,800,042 shares worth $213M in total. Ra Capital Management, L.p. reported the largest position.
- Are funds buying or selling KPTI?
- In Q2 2026, 34 managers opened new KPTI positions, 29 added, 14 trimmed and 14 sold out. Managers that filed in both quarters added a net 3,754,760 shares.
- How current is this KPTI institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to KPTI by CUSIP. Options are left out. KPTI news and filings · KPTI insider trades · Top funds